Financial Performance - The company's operating revenue for Q3 2025 was ¥288,631,567.14, a decrease of 9.70% compared to the same period last year[4] - The total profit for the period was ¥28,720,387.90, reflecting a significant decline of 83.93% year-over-year[4] - The net profit attributable to shareholders was ¥29,915,841.81, down 81.55% from the previous year[4] - The basic earnings per share for the current period was ¥0.07, a decrease of 81.58% year-over-year[4] - The net profit excluding non-recurring gains and losses for the current period was ¥31,487,449.01, a decrease of 44.89% year-over-year[4] - Total operating revenue for the first three quarters of 2025 was CNY 741.75 million, a decrease of 12.93% compared to CNY 851.84 million in the same period of 2024[19] - Net profit for the first three quarters of 2025 was a loss of CNY 55.07 million, compared to a profit of CNY 220.77 million in the same period of 2024[20] - The company reported a significant decrease in net profit attributable to shareholders, which was a loss of CNY 50.80 million in 2025 compared to a profit of CNY 227.35 million in 2024[20] - The comprehensive income attributable to the parent company's owners for the first three quarters of 2025 was -52,916,564.33 RMB, compared to 229,304,833.45 RMB in the same period of 2024, indicating a significant decline[21] - Basic and diluted earnings per share for the first three quarters of 2025 were both -0.12 RMB, down from 0.54 RMB in the same period of 2024[21] Expenses and Costs - Research and development expenses totaled ¥94,910,464.56, an increase of 28.33% compared to the same quarter last year, representing 32.88% of operating revenue[4] - Total operating costs for the first three quarters of 2025 were CNY 685.55 million, down 7.56% from CNY 741.47 million in 2024[19] - The company is focusing on cost control measures, as evidenced by a reduction in sales expenses from CNY 326.66 million in 2024 to CNY 272.03 million in 2025[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,876,237,650.64, a decrease of 5.60% from the end of the previous year[5] - Total assets decreased to CNY 4.88 billion in 2025 from CNY 5.17 billion in 2024, indicating a contraction in the company's asset base[16] - Total liabilities decreased to CNY 1.16 billion in 2025 from CNY 1.19 billion in 2024, showing a reduction in financial obligations[16] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥31,168,333.28, down 80.79% compared to the same period last year[4] - Net cash flow from operating activities for the first three quarters of 2025 was 31,168,333.28 RMB, a decrease of 80.8% compared to 162,244,732.53 RMB in the same period of 2024[22] - Cash inflow from operating activities totaled 1,031,888,173.09 RMB, slightly down from 1,038,292,103.01 RMB in the previous year[22] - Cash outflow from operating activities increased to 1,000,719,839.81 RMB, compared to 876,047,370.48 RMB in the same period of 2024[22] - Cash flow from investing activities generated a net inflow of 138,140,039.42 RMB, compared to 134,415,817.02 RMB in the same period of 2024[23] - Cash inflow from investing activities was 583,495,601.60 RMB, down from 1,198,249,243.58 RMB in the previous year[23] - Cash flow from financing activities resulted in a net outflow of -100,519,702.26 RMB, contrasting with a net inflow of 33,105,508.60 RMB in the same period of 2024[23] - The ending balance of cash and cash equivalents as of September 2025 was 2,129,942,698.64 RMB, an increase from 1,959,830,216.33 RMB at the end of September 2024[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,908[12] - The largest shareholder, Ding Zhao, holds 114,066,766 shares, representing 26.93% of total shares[12] - The number of shares held by the top ten shareholders includes significant holdings by Huang Qianyi (27,219,439 shares, 6.43%) and Wang Xiaopeng (17,037,557 shares, 4.02%)[12] - The total number of shares held by shareholders with frozen shares includes 27,219,439 shares held by Huang Qianyi[12] - The company has not reported any changes in the participation of major shareholders in margin trading activities[14] - The company has not received any declarations regarding related party relationships among shareholders[14] Market Outlook - The company anticipates continued challenges in the market, which may affect future performance and strategic initiatives[20] Accounting Standards - The company did not apply new accounting standards or interpretations starting in 2025[24]

Group 1 - The core point of the article is that Huiyu Pharmaceutical reported a decline in both revenue and net profit for the third quarter and the first three quarters of the year [1] Group 2 - For the third quarter, the company's revenue was 289 million yuan, a year-on-year decrease of 9.70% [1] - The net profit for the third quarter was 29.92 million yuan, reflecting a significant year-on-year decline of 81.55% [1] - For the first three quarters, the total revenue was 742 million yuan, which represents a year-on-year decrease of 12.92% [1] - The net profit for the first three quarters was -50.80 million yuan, indicating a year-on-year decline of 122.35% [1]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-083 四川汇宇制药股份有限公司 关于自愿披露公司参与全国药品集中采购拟中选的公告 本次公司拟中选的产品于 2024 年 10 月获得国家药品监督管理局签发的《药 品注册证书》，本次中标前暂未产生销售收入。 本次集中采购是国家组织的第十一批药品集中带量采购，采购周期中，医疗 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）全资子公司四川汇宇海玥 医药科技有限公司参与了国家组织药品联合采购办公室（以下简称"联采办"） 组织的第十一批全国药品集中采购的投标工作，根据联采办于 2025 年 10 月 28 日在上海阳光医药采购网（https://www.smpaa.cn）发布的《全国药品集中采购拟 中选结果公示》显示，公司 1 个产品拟中标本次集中采购，现将相关情况公告如 下： | 序 | 拟中选 | 适应症 | 包装 | 计价 | 拟中选 | 采购周期 | | | --- | --- | --- | --- | --- ...

人民财讯10月28日电，汇宇制药(688553)10月28日公告，公司全资子公司四川汇宇海玥医药科技有限公 司参与了国家组织药品联合采购办公室组织的第十一批全国药品集中采购的投标工作，公司1个产品(美 索巴莫注射剂)拟中标本次集中采购。本次公司拟中选的产品于2024年10月获得国家药品监督管理局签 发的《药品注册证书》，本次中标前暂未产生销售收入。 ...

Core Points - The stock of Huayu Pharmaceutical (688553.SH) closed at 21.28 yuan, reflecting a decline of 2.96% and is currently in a state of breaking below its initial public offering price [1] - Huayu Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [1] - On the first day of trading, the stock reached a peak of 42.59 yuan, marking the highest price since its listing [1] - The total funds raised from the IPO amounted to 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, which was 453 million yuan more than the original plan [1] - The company intended to raise 1.907 billion yuan for projects including the construction of a second phase of the EU-standard injection production base and the establishment of an innovative drug research institute, as well as to supplement working capital [1] - The total issuance costs were 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities amounting to 98.875 million yuan [1]

上市当日，汇宇制药盘中最高报42.59元，创上市以来股价最高点。 中国经济网北京10月23日讯汇宇制药(688553.SH)今日收报21.28元，跌幅2.96%。目前该股处于破发状 态。 2021年10月26日，汇宇制药在上交所科创板上市，公开发行股票6360.00万股，发行价格为38.87元/股， 保荐机构、主承销商为中信建投（601066）证券，保荐代表人为杨泉、田斌，联席主承销商为国都证 券。 汇宇制药发行费用合计1.11亿元，其中中信建投证券、国都证券获得承销费9887.48万元。 汇宇制药发行募集资金总额为24.72亿元，扣除发行费用后，募集资金净额为23.61亿元。汇宇制药最终 募集资金净额比原计划多4.53亿元。汇宇制药于2021年10月18日披露的招股书显示，公司拟募集资金 19.07亿元，分别用于汇宇欧盟标准注射剂产业化基地(二期)项目、汇宇创新药物研究院建设项目、补充 流动资金。 ...

永赢医药健康A（008618）成立日期2020年5月20日，最新规模2417.75万。今年以来收益14.74%，同类 排名3177/4218；近一年收益12.38%，同类排名2997/3875；成立以来收益5.65%。 永赢医药健康A（008618）基金经理为单林。 10月23日，汇宇制药跌5.02%，截至发稿，报20.83元/股，成交7570.42万元，换手率1.04%，总市值 88.24亿元。 资料显示，四川汇宇制药股份有限公司位于四川省内江市市中区汉阳路333号3幢，成立日期2010年10月 12日，上市日期2021年10月26日，公司主营业务涉及肿瘤领域药物和复杂注射剂药物的研发、生产和国 内外销售。主营业务收入构成为：药品销售97.27%，技术服务1.66%，其他1.07%。 从基金十大重仓股角度 数据显示，永赢基金旗下1只基金重仓汇宇制药。永赢医药健康A（008618）二季度持有股数21.96万 股，占基金净值比例为3.56%，位居第十大重仓股。根据测算，今日浮亏损失约24.16万元。 截至发稿，单林累计任职时间1年125天，现任基金资产总规模31.43亿元，任职期间最佳基金回报 103.91%， ...

Group 1 - The core point of the news is that Sichuan Huiyu Pharmaceutical Co., Ltd. experienced a stock decline of 5.24%, with a current share price of 19.90 yuan and a total market capitalization of 8.43 billion yuan [1] - The company was established on October 12, 2010, and went public on October 26, 2021, focusing on the research, production, and sales of oncology drugs and complex injectable drugs [1] - The main revenue composition of the company includes 97.27% from drug sales, 1.66% from technical services, and 1.07% from other sources [1] Group 2 - From the perspective of fund holdings, Dachen Fund has a significant position in Huiyu Pharmaceutical, with its Dachen Medical Health Stock A fund holding 431,500 shares, accounting for 4.07% of the fund's net value [2] - The Dachen Medical Health Stock A fund has a current scale of 153 million yuan and has achieved a year-to-date return of 28.54%, ranking 1895 out of 4220 in its category [2] - The fund manager, Yang Ting, has been in the position for 11 years and 114 days, with the best fund return during his tenure being 77.63% [2]

Group 1 - The core point of the news is that Sichuan Huiyu Pharmaceutical Co., Ltd. experienced a stock decline of 6.24%, with the current share price at 20.00 CNY and a total market capitalization of 8.472 billion CNY [1] - The company specializes in the research, production, and sales of drugs in the oncology field and complex injectable drugs, with 97.27% of its revenue coming from drug sales [1] - The company was established on October 12, 2010, and went public on October 26, 2021 [1] Group 2 - From the perspective of fund holdings, Yongying Fund has a significant position in Huiyu Pharmaceutical, with its Yongying Medical Health A fund holding 219,600 shares, representing 3.56% of the fund's net value [2] - The fund has reported a floating loss of approximately 292,100 CNY as of the latest update [2] - Yongying Medical Health A fund has a total scale of 24.1775 million CNY and has achieved a year-to-date return of 18.06% [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688553 证券简称：汇宇制药 公告编号：2025-082 ● 近日，股东黄乾益先生分别被四川自由贸易试验区人民法院、四川省泸州市江阳区人民法院、浙江省 杭州市拱墅区人民法院轮候冻结合计6,070,738股。截至2025年10月9日，股东黄乾益先生累计被轮候冻 结股份数6,350,738股，占其所持股份比例为23.33%，占公司总股本比例为1.50%。 四川汇宇制药股份有限公司 持股5%以上股东股份被司法冻结及轮候冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 截至公告披露日，四川汇宇制药股份有限公司（以下简称"公司"）股东黄乾益直接持有公司股份 27,219,439股，占公司总股本比例为6.43%。 ● 近日，股东黄乾益先生所持公司股份被四川省泸州市江阳区人民法院司法冻结5,788,307股。截至2025 年10月9日，股东黄乾益先生累计司法冻结股份数27,219,439股，占其所持股份比例为100%，占公司总 股本比例为6.4 ...